Charles River Laboratories Shares Leap 8.7% on Optimistic 2024 Guidance
In a notable movement within the pharmaceutical sector, Charles River Laboratories International saw its shares surge by 8.7% to $239.28. This leap is attributed to the company's forward-looking 2024 guidance, promising strong returns and potentially reshaping investor sentiment. With the stock down approximately 5% over the past year, this recent surge marks a significant turnaround, positioning Charles River Laboratories as the third best performer in the S&P 500 to date.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
